For help on how to get the results you want, see our search tips.
7 results
Medicine
Summaries of opinion Remove Summaries of opinion filter
Referrals Remove Referrals filter
Orphan designations Remove Orphan designations filter
Medicine type
Exceptional circumstances Remove Exceptional circumstances filter
Conditional approval Remove Conditional approval filter
Accelerated assessment Remove Accelerated assessment filter
Biosimilar Remove Biosimilar filter
Opinion status
Positive Remove Positive filter
-
List item
Summary of opinion: Retsevmo
selpercatinib, opinion date: 22/04/2022, Positive, Last updated: 22/04/2022 -
List item
Summary of opinion: Crysvita
burosumab, opinion date: 23/06/2022, Positive, Last updated: 24/06/2022 -
List item
Summary of opinion: Ranivisio
ranibizumab, opinion date: 23/06/2022, Positive, Last updated: 24/06/2022 -
List item
Summary of opinion: Vegzelma
bevacizumab, opinion date: 23/06/2022, Positive, Last updated: 21/06/2022 -
List item
Summary of opinion: Roctavian
Valoctocogene roxaparvovec, opinion date: 23/06/2022, Positive, Last updated: 24/06/2022 -
List item
Summary of opinion: Tecartus (new)
Autologous peripheral blood T cells CD4 and CD8 selected and CD3 and CD28 activated transduced with retroviral vector expressing anti-CD19 CD28/CD3-zeta chimeric antigen receptor and cultured, opinion date: 21/07/2022, Positive, Last updated: 22/07/2022 -
List item
Summary of opinion: Retsevmo (new)
selpercatinib, opinion date: 21/07/2022, Positive, Last updated: 22/07/2022